GU Cancers 2019 | Sacituzumab govitecan in patients with previously treated mUC

Scott Tagawa

Scott Tagawa, MD, MS, of the Weill Cornell Medicine, New York City, NY, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He gives us a comprehensive update on the Phae I/II trial of Sacituzumab govitecan, detailing the study aims, design, results and conclusions.

Share this video  
Similar topics